FY2025 EPS Estimates for ACRS Cut by Cantor Fitzgerald

Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - Research analysts at Cantor Fitzgerald reduced their FY2025 earnings per share estimates for Aclaris Therapeutics in a report issued on Tuesday, March 18th. Cantor Fitzgerald analyst P. Agrawal now expects that the biotechnology company will earn ($0.62) per share for the year, down from their prior forecast of ($0.54). Cantor Fitzgerald has a "Overweight" rating on the stock. The consensus estimate for Aclaris Therapeutics' current full-year earnings is ($0.82) per share.

ACRS has been the subject of several other research reports. Scotiabank started coverage on shares of Aclaris Therapeutics in a research note on Friday, March 7th. They issued a "sector outperform" rating and a $15.00 price objective for the company. StockNews.com downgraded Aclaris Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, February 8th. Finally, HC Wainwright upgraded Aclaris Therapeutics from a "neutral" rating to a "buy" rating and set a $20.00 price objective for the company in a research note on Monday, December 23rd. One equities research analyst has rated the stock with a sell rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $11.67.

Remove Ads

Aclaris Therapeutics Price Performance

Shares of Aclaris Therapeutics stock traded up $0.10 during trading hours on Thursday, hitting $1.70. The company had a trading volume of 1,372,163 shares, compared to its average volume of 1,166,988. The company's 50-day moving average is $2.15 and its two-hundred day moving average is $2.22. Aclaris Therapeutics has a twelve month low of $0.95 and a twelve month high of $5.17. The company has a market cap of $183.46 million, a P/E ratio of -3.27 and a beta of 0.48.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of ACRS. Jefferies Financial Group Inc. increased its stake in Aclaris Therapeutics by 253.9% in the 4th quarter. Jefferies Financial Group Inc. now owns 40,700 shares of the biotechnology company's stock valued at $101,000 after buying an additional 29,200 shares during the period. Alpine Global Management LLC purchased a new position in Aclaris Therapeutics during the fourth quarter worth about $38,000. Velan Capital Investment Management LP purchased a new stake in Aclaris Therapeutics in the 4th quarter valued at approximately $67,000. Squarepoint Ops LLC increased its position in Aclaris Therapeutics by 108.3% during the 4th quarter. Squarepoint Ops LLC now owns 292,892 shares of the biotechnology company's stock worth $726,000 after purchasing an additional 152,312 shares during the period. Finally, Man Group plc purchased a new position in shares of Aclaris Therapeutics during the 4th quarter worth approximately $133,000. Institutional investors and hedge funds own 98.34% of the company's stock.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.